Blockchain Registration Transaction Record

Calidi Biotherapeutics Unveils Promising CLD-401 Data at ASCO

Calidi Biotherapeutics reveals groundbreaking CLD-401 data at ASCO, showcasing advances in systemic oncolytic targeted immunotherapies for cancer treatment.

This news is significant as it highlights a breakthrough in cancer treatment, offering hope for patients with hard-to-treat cancers. Calidi Biotherapeutics' innovative approach to immunotherapy could revolutionize how cancers are treated, particularly those with high unmet medical needs. The development of therapies that can effectively target and treat metastatic cancer sites without being cleared by the immune system represents a major advancement in oncology.